Transforming the treatment of neurodegenerative disorders by restoring and protecting neurological function

Our Approach

We are a clinical-stage biopharmaceutical company focused on revolutionizing the treatment of neurodegenerative diseases with first-in-class nanotherapeutics. Our science harnesses the extraordinary properties of elemental nanocrystals for therapeutic use.

Understand Our Science

Our Pipeline

Our nanotherapeutics target cellular energy impairments that are common to many diseases. This novel approach has allowed us to explore broad applications of our drugs across therapeutic areas.

Explore Our Pipeline

Our Team

We believe in applying innovations to therapeutic challenges that currently have no effective solutions. With the right mix of experience, expertise, and creativity, we are changing the landscape of clinical development.

Meet Our Team

Our Clinical Trials

Results from the Phase 2 REPAIR clinical studies provided evidence for central nervous system target engagement of Clene’s lead therapeutic candidate, CNM-Au8®, a gold nanocrystal suspension, in the brains of both Multiple Sclerosis (MS) and Parkinson’s Disease (PD) patients.

Review Our Latest News